The Alleged Link Between Valsartan And Cancer
- Written by: Daily Bulletin
Image source
In recent years, numerous reports have come up alleging a link between Valsartan and cancer, leaving thousands of people with burning questions and serious concerns.
When faced with this kind of situation, having a good Valsartan cancer lawsuit attorney on your side is crucial. They can help you navigate the legal system, understand your rights, and secure compensation for any harm you may have suffered.
Let's dive deeper into the alleged link between Valsartan and cancer.
What is Valsartan?
Valsartan is a common medication used to treat high blood pressure, heart failure, and other cardiovascular conditions. It’s a prescription drug that’s been around since the late 1990s.
Valsartan and Cancer
Studies have suggested that prolonged exposure to N-nitrosodimethylamine (NDMA) or N-nitrosodiethylamine (NDEA) can increase the risk of certain types of cancer, including liver and kidney cancer. The extent of the risk is still being investigated, but the concerns are real and the stakes are high.
In the wake of these alarming reports, victims began filing lawsuits against pharmaceutical companies. The lawsuits allege that these companies knew or should have known about the presence of NDMA and NDEA in their Valsartan products and failed to take appropriate action to protect consumers.
The Start of the Controversy
In 2018, reports surfaced that Valsartan manufactured by various pharmaceutical companies contained NDMA and NDEA.
-
NDMA and NDEA
NDMA and NDEA are both known carcinogens, meaning they can increase the risk of developing cancer. N-nitrosodimethylamine (NDMA) is a potent carcinogen that can damage DNA, leading to mutations and potentially causing tumors.
NDMA is also a well-known environmental contaminant with links to a range of industries, including food processing and wastewater treatment. On the other hand, there is N-nitrosodiethylamine (NDEA), a structural analog of NDMA. NDEA is a known liver carcinogen with the potential to cause damage to DNA and lead to cancerous tumors.
It can enter the body through ingestion or inhalation and has been linked to occupational exposure in industries such as rubber manufacturing and pesticide production.
The mechanisms by which NDMA and NDEA cause cancer are complex, but both are believed to interact with DNA in a way that can result in mutations and cell damage. Over time, these changes can lead to the uncontrolled cell growth characteristic of cancer.
This discovery sparked widespread concern and led to the recall of multiple lots of Valsartan from various manufacturers around the world.
Cancers that may be associated with NDMA include:
- Liver cancer
- Kidney cancer
- Colorectal cancer
- Stomach or gastric cancer
- Bladder cancer
- Pancreatic cancer
- Lung cancer
- Nasal cancer
Cancer in Animals
NDMA has been extensively researched in animals and has been linked to an increased incidence of cancer among them. According to these studies, the U.S. Environmental Protection Agency categorizes NDMA as a possible human carcinogen, suggesting that it is likely to cause cancer in humans.
Studies have indicated a potential connection between NDMA exposure and liver damage, which may lead to the development of liver cancer and other conditions due to NDMA-induced liver damage.
Furthermore, NDMA is believed to be connected to cancers affecting various organs such as the stomach, bladder, small intestine, colon/rectum, esophagus, prostate, and pancreas, as well as leukemia, non-Hodgkin’s lymphoma, and multiple myeloma.
Daily Bulletin
